

## 28-Day Check-In

Monitoring and assessing your asthma symptoms, whether good or bad, will help you maintain an open dialogue with your doctor. That's why you should check your snapshot score every 4 weeks, prior to each injection of NUCALA.


NUCALA is an add-on, prescription maintenance treatment for patients 12 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems.

To get your snapshot scores, circle the number that matches your symptoms during the past 4 weeks.

**A** During the past 4 weeks, your asthma symptoms have been:




**B** On average, during the past 4 weeks, how often were you awakened by your symptoms at night?



**C** During the past 4 weeks, how often did you experience shortness of breath because of your asthma?



**D** During the past 4 weeks, how often have you used your rescue inhaler?



**E** During the past 4 weeks, how much were your daily activities limited because of your asthma?



### Important Safety Information

**Do not use NUCALA** if you are allergic to mepolizumab or any of the ingredients in NUCALA.

Do not use to treat sudden breathing problems.

**Please see additional Important Safety Information on Page 2.**

**Nucala**   
**(mepolizumab)**  
for Subcutaneous Injection  
100 mg/vial

Now that you have your snapshot scores, be sure to write today's date and your scores in the chart below.

Date	Snapshot Scores				
	A	B	C	D	E



Repeat this process prior to each treatment and share with your doctor. Write and track your snapshot scores in *A Guide to Your First Treatment*.

### Important Safety Information (cont'd)

**NUCALA can cause serious side effects, including:**

- **allergic (hypersensitivity) reactions, including anaphylaxis.** Serious allergic reactions can happen after you get your injection of NUCALA. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
  - swelling of your face, mouth, and tongue
  - breathing problems
  - fainting, dizziness, feeling light-headed (low blood pressure)
  - rash
  - hives

- **Herpes zoster infections** that can cause shingles have happened in people who received NUCALA.

**Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you:**

- are taking oral or inhaled corticosteroid medicines. **Do not** stop taking your other asthma medicines, including your corticosteroid medicines, unless instructed by your healthcare provider because this may cause other symptoms to come back.
- have a parasitic (helminth) infection.
- are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby.
  - A pregnancy registry for women who receive NUCALA while pregnant collects information about the health of you and your baby. You can talk to your healthcare provider about how to take part in this registry or you can get more information and register by calling 1-877-311-8972 or visit [www.mothertobaby.org/asthma](http://www.mothertobaby.org/asthma).
- are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first.
- are taking prescription and over-the-counter medicines, vitamins, and herbal supplements.

**The most common side effects of NUCALA include:** headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and weakness (fatigue).

**Please see additional Important Safety Information on Page 1.**

**Please see full Prescribing Information, including Patient Information Leaflet, for NUCALA available at [NUCALA.com](http://NUCALA.com).**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Trademarks are owned by or licensed to the GSK group of companies.



©2018 GSK group of companies or its licensor.  
Printed in USA. 823303R0 January 2018

**Nucala**   
**(mepolizumab)**  
for Subcutaneous Injection  
100 mg/vial